Nefazodone and the Treatment of Nonparaphilic Compulsive Sexual Behavior: A Retrospective Study
J Clin Psychiatry 2000;61:282-284
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Recent reports suggest that
individuals with nonparaphilic compulsive sexual behavior can be
treated pharmacologically with selective serotonin reuptake
inhibitors (SSRIs) to control sexual obsessions and compulsions.
However, these medications have produced sexual side effects that
may limit long-term use, particularly as individuals strive to
reestablish healthy sexual relationships. Nefazodone is an
antidepressant that is not associated with the sexual side
effects of other SSRIs. We examined retrospective data from our
clinic to investigate whether nefazodone has utility in the
treatment of nonparaphilic compulsive sexual behavior.
Method: Fourteen subjects who met DSM-IV
criteria for sexual disorder NOS as well as criteria used by our
research group for nonparaphilic compulsive sexual behavior and
who had been treated with nefazodone were selected from patient
charts at our clinic. The treating physician abstracted
information from the charts regarding comorbid psychiatric
conditions, medication, dosage, treatment response, and side
Results: In this study, the mean dosage of
nefazodone was 200 mg/day. Of the subjects who remained on
long-term nefazodone therapy, 6 (55%) reported good control of
sexual obsessions and compulsions, and 5 (45%) reported a
remission of sexual obsessions and compulsions.
Conclusion: Results from this preliminary
retrospective study suggest that nefazodone decreases the
frequency of sexual obsessions and compulsions but does not
produce the undesired sexual side effects caused by SSRI